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Introduction
Ascites is a term that describes a pathologic accumula-
tion of fluid within the peritoneal cavity. It can develop as
a result of liver disease, congestive heart failure or nephro-
tic syndrome, and is not an uncommon complication
accompanying some gynecologic diseases. It is, therefore,
important that health care workers consider gynecologic
problems among the potential differential diagnoses in
patients with ascites. The following review explores the
gynecologic diseases that can result in ascites.
Ovarian Malignancy
Epithelial ovarian cancer is possibly the most common
type of cancer leading to malignant ascites [1–4]. In a
2-year, single institute, retrospective analysis, 37.7% of
patients with ovarian cancer developed ascites, account-
ing for a quarter of the cases of malignant ascites [1].
Paracentesis is commonly used to evaluate ascites and
to make a differential diagnosis. Around 70% of patients
with ovarian cancer demonstrate cytologic evidence 
of ascites [5]. Nevertheless, in some cases where an
ovarian malignancy is suspected, paracentesis may 
be withheld because of the risk of abdominal wall
metastases developing at the paracentesis entry sites,
especially since the occurrence of this phenomenon,
together with the presence of ascites, is highly associ-
ated with advanced tumor stage [6,7]. The reported
incidence of tumor implantations at trocar or punc-
ture sites after invasive diagnostic procedures varies
widely, ranging from 1.2–13.7% [6–9]. The mechanism
behind puncture site metastasis is not well under-
stood, but it is likely to be related to direct implanta-
tion following surgical trauma [10,11]. The concept of
standard therapy for advanced ovarian cancer using
primary debulking surgery followed by chemotherapy
has recently been challenged by an alternative option
using neo-adjuvant chemotherapy followed by interval
debulking surgery [12–14]. This would increase the
possibility for performing diagnostic paracentesis before
getting a definite diagnosis. Although the presence of
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abdominal wall metastasis does not seem to be signif-
icantly correlated with survival [7], the potential danger
of performing diagnostic paracentesis should always be
kept in mind.
The presence of malignant ascites is usually indica-
tive of a poor prognosis; however, malignant ascites of
ovarian origin has a relatively higher survival rate than
that of other origins [1–4]. The management of malig-
nant ascites caused by operable ovarian cancer differs
from that of other cancers. The mainstay of therapy
for ascites accompanying ovarian cancer, unlike other
cancers, is attempted removal of all detectable tumors
by debulking surgery, followed by adjuvant chemo-
therapy. The ascites will subside if the ovarian cancer is
responsive to chemotherapy. However, for those with
malignant ascites caused by recurrent or refractory
ovarian cancer, palliative treatment by serial paracen-
tesis or drainage is a possible option to provide symp-
tomatic relief [15–17]. Infectious morbidity is a major
concern associated with invasive procedures. In addi-
tion, the removal of large volumes of ascitic fluid may
result in protein loss and hypovolemia, with subsequent
circulatory problems. Although diuretics and salt re-
striction have been empirically used in the treatment of
ascites caused by different kinds of medical illnesses,
the effectiveness of these approaches for malignant
ascites has yet to be proven. Treatment of the causative
malignant cells by intraperitoneal cytotoxic chemother-
apy provides another possible approach for controlling
malignant ascites. Various antineoplastic agents, in-
cluding cisplatin, carboplatin, 5-fluorouracil and leu-
covorin, as well as metalloproteinase inhibitors, have
been used to inhibit ascites formation. Intraperitoneal
agents that block vascular endothelial growth factor have
also been found to be a promising therapy for ascites
related to carcinoma in both animal models and human
clinical trials [18,19]. Some experimental strategies, such
as the use of radiolabeled antibodies and immunother-
apy, have been reported to be alternative options for
ovarian cancer patients with malignant ascites [20].
Pelvic or Peritoneal Tuberculosis
Tuberculosis is a mycobacterial infection that most
commonly manifests as pulmonary disease, but may
also affect extrapulmonary sites [21–23], such as the
abdominopelvic region. It usually affects women of
reproductive age [24]. The clinical presentation of pelvic
tuberculosis is non-characteristic, and includes vague
pelvic pain, abdominal distension, weight loss or fever.
Infertility is a relatively frequent complaint in female
patients with pelvic tuberculosis [25]. On diagnostic
imaging, pelvic tuberculosis may appear as ascites,
peritoneal nodules, omental or peritoneal thickening, or
adnexal masses. The clinical manifestations and imaging
features can mimic disseminated carcinomatosis
[26–36]. However, there are some subtle ultrasonog-
raphic differences that can help to distinguish between
pelvic tuberculosis and ovarian cancer: (1) tuberculous
ovarian masses are usually almost unenlarged; (2) the
septum inside the tuberculous ovarian mass is usually
composed of multiple, delicate, incomplete septa,
rather than of thick bands as found in ovarian malig-
nancy; and (3) the blood vessels supplying the tuber-
culous implants are present in high impedance, which
reflects vascular resistance, calculated after measuring
peak systolic (S) and peak diastolic (D) velocities of
blood flow by colored Doppler ultrasound using the
formula: resistance index = (S − D)/S [37].
Ascites is a common presentation of pelvic tuber-
culosis. However, the diagnostic value of paracentesis in
ascitic fluid analysis is still inconclusive. The sensitivity
of direct preparations of ascitic fluid, for either acid-
fast stain or tuberculosis culture, is relatively low [38].
Moreover, the long turnaround time required for cul-
ture of the microorganism makes this method imprac-
tical. Currently, ascitic fluid analysis by polymerase chain
reaction for mycobacteria or for elevated adenine deam-
inase levels is considered to be a reliable diagnostic
technique [39,40]. Blind percutaneous peritoneal biopsy
was first advocated 40 years ago as the procedure of
choice in cases of early tuberculous peritonitis [41], with
varying reported rate of success [42]. Peritoneal biopsy
was performed at the left lower quadrant of the ab-
domen, adjacent to the rectus muscle, using an Abrams
needle or Cope needle, under local anesthesia. The
limitations include complications such as bowel perfo-
ration and even mortality, and the technique is con-
traindicated in the absence of ascites. However, these
limitations could be overcome by using ultrasound- or
computed tomography-guided needle biopsy, which is
deserving of further study [43]. Even though pelvic
tuberculosis is usually secondary to previous tubercu-
losis infection, the tuberculin skin test and chest
roentgenograms do not help to distinguish patients
with pelvic tuberculosis [44,45]. Most patients in the
literature were diagnosed by exploratory laparotomy
and by confirmatory histopathology.
With significant improvements in laparoscopic tech-
niques, laparoscopy has become an effective diagnos-
tic tool to confirm uncertain abdominal conditions
[46], and provides an alternative to traditional laparo-
tomy [47] and a better choice than exploratory laparo-
tomy [48]. The characteristic laparoscopic appearance
includes free ascites with multiple yellowish-white 
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nodules of tubercles on the visceral and parietal perito-
neum, peritoneal or visceral adhesion, and occasionally
inflamed hemorrhagic areas on the peritoneum [42].
The results of a large case series that investigated
laparoscopic evaluation (combined with peritoneal
biopsy) of ascites of unknown origin found that a defi-
nite diagnosis was established in 80–97% of cases [42,
49–51]. Patients diagnosed with pelvic tuberculosis
had a satisfactory response to anti-tuberculosis drugs
and ascites generally resolved after anti-tuberculosis
treatment [29,32].
Ovarian Hyperstimulation Syndrome 
(OHSS)
Ascites is a clinical manifestation of OHSS. OHSS is 
an iatrogenic complication of ovarian stimulation for
assisted reproductive techniques [52,53]. The patho-
genesis of OHSS may be associated with an exagger-
ated response to gonadotropin, resulting in increased
vascular permeability via the activity of vascular endothe-
lial growth factor, tumor necrosis factor, and interleukin.
The syndrome is characterized by cystic enlargement
of the ovaries and fluid leakage from the blood vessels
into the interstitial space [52]. The clinical presentation
of OHSS varies considerably, ranging from mild disten-
sion, discomfort and nausea, to dyspnea, oliguria,
increased hematocrit, thromboembolism, or even abnor-
mal creatinine clearance, liver dysfunction or respiratory
distress. The diagnosis is usually established by a history
of assisted reproductive technique, clinical appear-
ance, and specific ultrasound findings. Examination of
the abdomen should be deferred to prevent rupture of
enlarged ovaries and subsequent hemorrhage. The
most recent classification of OHSS was introduced in
1999 [54] and differs from previous systems in that a
mild degree of OHSS is omitted from the classification,
while severe OHSS is classified into three grades,
depending on general clinical symptoms and labora-
tory parameters. The most effective treatment for
OHSS is prevention [55]. For OHSS-associated
ascites, ultrasound-guided paracentesis has been
shown to result in the relief of abdominal distension,
improvement of dyspnea, increased diuresis, and
decreased hematocrit [56–59]. Concurrent intravenous
rehydration and colloid solution supplement are needed
to maintain euvolemia [60]. Only a few pharmacologic
interventions are available to ameliorate extravascular
leakage; diuretics play no role [61], but dopamine
treatment and dopamine prodrugs have been used to
reduce ascites [62,63]. A prospective, randomized,
double-blind study in oocyte donors at risk of developing
OHSS found that administration of cabergoline, a
potent dopamine agonist, significantly reduced the
occurrence of ascites [64].
Meigs Syndrome, Pseudo-Meigs Syndrome,
and Pseudo-pseudo Meigs Syndrome
Meigs syndrome is defined as a triad of benign ovarian
tumors accompanied by ascites and pleural effusion
[65]. The ovarian tumor may be a fibroma, thecoma or
granulose tumor, of which ovarian fibromas are the most
common cause of Meigs syndrome. Ovarian fibromas
constitute less than 5% of all ovarian tumors, and only
1% of diagnosed cases have been associated with the
clinical picture of Meigs syndrome [66,67]. Meigs syn-
drome is a rare clinical entity. Pseudo-Meigs syndrome
is a variant with an identical clinical constellation, but
without the original benign tumor cell types described
by Meigs [68]. The benign tumors include those of the
fallopian tubes and uterus, mature teratomas, struma
ovarii, and ovarian leiomyomas. The distinction between
Meigs syndrome and pseudo-Meigs syndrome is mostly
academic, because the therapeutic strategy is the same
in both cases [69]. The pathophysiology of ascites in
Meigs syndrome or pseudo-Meigs syndrome remains
enigmatic. Some have speculated that the accumulation
of peritoneal fluid is caused by irritation of the peritoneal
surfaces or by direct pressure on the surrounding lym-
phatics or vessels by the solid ovarian tumor [70–72].
Other proposed mechanisms suggest that the ascites
is caused by fluid secretion from the ovarian tumor, or
as a result of increased capillary permeability via release
of mediators from the tumor [65]. The ascites usually
disappears after resection of the tumor, and the progno-
sis is favorable.
In contrast to Meigs syndrome or pseudo-Meigs syn-
drome, pseudo-pseudo Meigs syndrome is a term that
describes patients with ascites, pleural effusion, and
enlarged ovaries secondary to systemic lupus erythe-
matosus [73]. The ovaries in pseudo-pseudo Meigs syn-
drome may be enlarged, but without evidence of a tumor.
Ascites in pseudo-pseudo Meigs syndrome is usually exu-
dative, and may be associated with activated mesothelial
cells in systemic lupus erythematosus [73,74].
Endometriosis
Endometriosis is a relatively common gynecologic dis-
ease, defined as the ectopic presence of endometrial
epithelium and stroma outside the uterine cavity.
Common clinical manifestations of endometriosis
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include pelvic pain, pelvic tenderness, dysmenorrhea,
dyspareunia, and a history of infertility. The fact that
endometriosis can rarely be associated with ascites is
not well known, even amongst practicing gynecologists.
Fewer than 50 such cases have been reported since the
first case was described in 1954 [75–91]. The vast
majority of patients were nulliparous non-Caucasian
women of reproductive age [76]. The ascites is mostly
massive and may be concurrent with pleural effusion.
Because endometriosis-associated ascites usually pres-
ents with a pelvic mass, poor appetite, weight loss and
elevated tumor markers for ovarian neoplasms, it is
commonly mistaken for ascites caused by ovarian neo-
plasms. Although cytologic examination via paracen-
tesis has been used successfully to detect endometriosis
in effusion [92], most patients were diagnosed by oper-
ative assessment and histologic confirmation. The path-
ogenesis of ascites associated with endometriosis is
speculative. Ascites can form as a result of the rupture of
endometriomas [89,93] or, rarely, from hepatic involve-
ment by cystic endometriosis [86]. The hypothesis that
endometrial cells shedding into the peritoneal cavity
may irritate the peritoneum, thereby leading to ascites, is
also widely accepted [94]. The definitive therapy for
endometriosis-related ascites is, therefore, to eliminate
ovarian function by oophorectomy. Medical treatment
using either a progestational agent or gonadotropin-
releasing hormone (GnRH) agonist is less reliable than
surgical castration, and may lead to a failed response
and a recurrence of ascites. However, GnRH agonists
have been used successfully to manage various kinds
of endometriosis and its related diseases [95–100].
Conclusion
This review indicates the need for clinicians to examine
possible gynecologic sources in female patients pre-
senting with ascites (Table). The initial evaluation of 
a female patient with ascites should rely on a detailed
history and physical examination. Paracentesis provides
a rapid and simple means of analyzing ascitic fluid, but
its effectiveness in determining the underlying cause is
limited in patients with ascites resulting from gyneco-
logic disorders. The treatment of ascites depends on
the cause of fluid retention. Most cases of gynecologic
disease-associated ascites can be resolved following an
accurate diagnosis and appropriate therapy.
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